Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Key takeaways
- On June 1, Wells Fargo lifted the price target on Mann Kind Corporation (NASDAQ:MNKD) to $11 from $10 and reiterated an Overweight rating.
- The FDA approval of Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes is strengthened by results from the pivotal INHALE-1 clinical trial.
- Copyright: dolgachov / 123RF Stock Photo
Wells Fargo Calls Mann Kind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Rameen Kasana Sat, June 13, 2026 at 10:31 PM GMT+7 2 min read MNKD Mann Kind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price target on Mann Kind Corporation (NASDAQ:MNKD) to $11 from $10 and reiterated an Overweight rating. The firm associated this target hike with Afrezza’s approval in pediatric patients, saying that the company’s commercial potential is a “show-me story.”
The FDA approval of Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes is strengthened by results from the pivotal INHALE-1 clinical trial. This announcement on May 29 extends Afrezza’s availability beyond adults, now catering to pediatric patients and caregivers as well. No wonder MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in.
Copyright: dolgachov / 123RF Stock Photo